HOA Appoints New CEO Jennifer Pichoske

Hematology-Oncology Associates of CNY (HOA) has appointed Jennifer Pichoske, MS, EMBA, AOCNP as Chief Executive Officer effective February 15, 2025. She succeeds Maryann Roefaro, MS, CEO since 2002, who is retiring.

HOA Appoints New CEO as of Feb. 15, 2025

Patient Newsletter 2024 December

Cancer Q&A with HOA: Providing hope to patients with Jennifer Pichoske

Patient Newsletter 2024 November

The Value of Lung Cancer Screenings - Debbie's Story

Lung cancer screenings are indicated for current and former heavy smokers. Learn why this former smoker says her screening saved her life!

View the story on SpectrumLocalNews.com.

Free Lung Cancer Screening

With November as Lung Cancer Awareness Month, Hematology/Oncology Associates of CNY (HOA) and CRA Medical Imaging (CRA) are offering FREE lung cancer screenings on Saturday, Nov. 2, 8 a.m. – 2 p.m. in three locations:

Survivors Share Their Stories

From in Good Health CNY, October 2024

 

Lilie Welych

A ‘thriver’ describes her cancer journey

By Mary Beth Roach

Lilie Welych considers herself a “thriver.”

And she proudly wears an alphabet-bead bracelet that spells out TNBC THRIVER.

TNBC stands for triple negative breast cancer, which she was diagnosed with two years ago.

Today, that thriver is in remission and NED (no evidence of disease).

Esophageal, MK3475-06C-U02 “KEYMAKER-U02”

A Phase 1/2 Open-Label, Umbrella Platform Design Study of MK-2870 With Pembrolizumab (MK-3475) and Chemotherapy in Participants with 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal. Substudy 06C

Esophageal, MK3475-06B-05 “KEYMAKER-U02”

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants with Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B.

Pages